Stryker maintains a strong position in medical technology, driven by double-digit organic growth in robotic surgery.
The MAKO robotic arm system boosts orthopedic procedures, as hospitals demand precision.
Analysts raised estimates: FY1 EPS rose from $13.49 to $14.99.
Market cap is $121.77 billion; shares trade at $317.51.
Operating margin is 64.7%, showing cost efficiency.
MedSurg division underperforms, indicating possible saturation.
Competition in robotics intensifies, with new entrants threatening.
